Clinical Effect of Atorvastatin Combined with Valsartan Treatment in Diabetic Patients with Early Nephropathy
YU Jian-min
XU Rui-ying
JING Shi-juan
YAN Da-jun
CUI Li-ping
GENG Ji-lu
Abstract：Objective To investigate clinical effect of atorvastatin combined with valsartan treatment in patients with early diabetic nephropathy ( DN) and its possible mechanisms. Methods 90 patients with definitive diagnosis of early DN were randomly divided into two groups, and 86 of them completed all the clinical experiments with complete records. Among them, 42 cases were in control group and 44 cases were in treatment group. Both groups were given routine treatment and in addition the control group was given valsartan (160 mg/d), while the treatment group was given valsartan (160 mg/d) and atorvastatin (20 mg/d) simultaneously, the treatment course was six months in both groups. Systolic blood pressure, diastolic blood pressure and mean arterial blood pressure, total cholesterol ( TC) , triglyceride ( TG) and low-density lipoprotein choles-terol ( LDL-C) , serum creatinine ( Cr) , blood urea nitrogen ( BUN) , serum cystatin C ( Cys-C) and retinol-binding protein ( RBP) and urinary albumin excretion rate ( UAER) were measured and compared before and after treatment in two groups. Results After six months' of treatment in two groups, systolic blood pressure, diastolic blood pressure and mean arterial pres-sure were significantly lower than that of baseline (P<0. 01), but there were no differences between the two groups (P>0. 05). After treatment, TC, TG and LDL-C in treatment group were significantly lower than that of baseline (P<0. 01), their values were significantly lower than that of control group, too (P<0. 01). Cys-C and RBP in treatment group significant-ly decreased (P<0. 05), while Cys-C and RBP in control group had no statistical change (P>0. 05), there were still differ-ences between the two groups after treatment. UAER in both group was significantly reduced, compared with the baseline (P<0. 01), while UAER in treatment group was lower than that of control group (P<0. 01). Cr and BUN level in the two groups also had a slight decrease, but there was no significantl change in the two groups. Conclusion Atorvastatin with val-sartan treatment in diabetic patients with nephropathy can reduce blood pressure and lipids effectively, and reduce Cys-C, RBP and UAER significantly, therefore it can obviously improve renal function and prevent the progress of diabetic nephropathy.
Keywords：AtorvastatinValsartanDiabetic nephropathyTreatment outcome
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 91-95 )